Factor VIII as a Novel Biomarker for Diagnosis, Prognosis, and Therapy Prediction in  Human Cancer and Other Disorders

Sheyda  Khalilian; Zahra  Mohajer; Soudeh  Ghafouri-Fard

doi:10.18502/ajmb.v16i2.14857

Sheyda Khalilian Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Zahra Mohajer Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Soudeh Ghafouri-Fard Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/ajmb.v16i2.14857

Keywords: Biomarkers, Cancer, Factor VIII, Prognosis

Abstract

Coagulation factor VIII (FVIII) is an essential cofactor in the coagulation cascade, encoded by the F8 gene on the long arm of chromosome X (Xq28). FVIII is normally circulated in complex with Von Willebrand factor (VWF) and has relevant emerging extracoagulative functions. Dysregulation of FVIII is associated with tumor progression, and could be used as a novel biomarker for tumor screening and monitoring. In breast cancer, bladder cancer, colorectal carcinoma, esophageal carcinoma, hepatocellular carcinoma and lung cancer, F8 is regarded as an oncogene. In coronary heart disease, hemophilia A and liver disease, F8 dysregulation has been recognized as a potential biomarker for disease diagnosis and prognosis. However, the basis of these differential expression levels remains to be understood. In this review, which is a mixture of literature review and bioinformatics analysis we described the biological functions and characteristics of FVIII, and also its expression level in non-malignant disorders and various cancers.